503A vs 503B vs 'Research Use Only': Three Supply Lanes Explained

A 503A pharmacy is a state-licensed pharmacy that compounds a drug for an identified patient with a prescription, and a 503B outsourcing facility is a compounder that registers with the FDA, follows current good manufacturing practice and is inspected by the agency. "Research use only" is neither: it describes material sold outside the pharmacy system altogether, with no prescription and no pharmacist involved.

None of the three is an FDA approval. The differences are in who makes the product, who it may go to and who checks the work.

Where the numbers come from

503A and 503B are sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional pharmacy compounding. Section 503B was added by the Drug Quality and Security Act, enacted on November 27, 2013, after the 2012 fungal meningitis outbreak and other serious harms linked to poor-quality compounded drugs.

Both sections exempt compounded drugs from certain requirements that apply to manufactured drugs, provided the compounder meets a list of conditions. The FDA states the consequence directly: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed.

At a glance

	503A pharmacy	503B outsourcing facility	Research use only
Who makes it	A licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician	A facility at one location that compounds sterile drugs and has elected to register with the FDA	A chemical supplier, outside pharmacy channels
Prescription	Required, for an identified individual patient	May or may not be patient-specific; can fill orders from health care providers	None. Sold as not for human use
Main overseer	State boards of pharmacy, with FDA surveillance and for-cause inspections	The FDA, on a risk-based inspection schedule	No routine review. The FDA acts when marketing points to human use
Manufacturing standard	Exempt from current good manufacturing practice	Current good manufacturing practice applies	None attached to the label
Exempt from new drug approval	Yes, if conditions are met	Yes, if conditions are met	Not applicable: it is not sold as a drug
Ingredients allowed	USP or NF monograph, component of an approved drug, or the 503A bulks list	The 503B bulks list, or a drug on the FDA shortage list	No list applies
Reporting to FDA	No twice-yearly product report	Adverse events, plus a product list every six months	No reporting system
FDA-approved product	No	No	No

503A: the traditional pharmacy

A 503A compounder is the pharmacy most people picture: a pharmacist preparing a medication for a named patient. The statute requires a valid prescription for an identified individual patient. In exchange, the compounded drug is exempt from three things: premarket approval, labeling with adequate directions for use, and current good manufacturing practice.

Day-to-day oversight belongs to the states. The FDA says state boards of pharmacy have primary responsibility for state-licensed pharmacies, while the agency itself conducts surveillance and for-cause inspections. A 503A pharmacy also may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available product.

503B: the outsourcing facility

A 503B outsourcing facility is a category Congress created for larger-scale sterile compounding. Registration is voluntary, but a facility that registers takes on obligations a pharmacy does not have. It must comply with current good manufacturing practice. It is inspected by the FDA on a risk-based schedule. It must report adverse events and give the agency a list of the drugs it compounded every six months. Its labels must carry the statement "This is a compounded drug."

In return, an outsourcing facility may distribute compounded drugs with or without patient-specific prescriptions, including to health care providers who order them for use in their practices. The statute says it is not required to be a licensed pharmacy, though compounding must be done by or under the direct supervision of a licensed pharmacist. It may not make drugs that are essentially copies of approved drugs.

The FDA publishes a list of registered outsourcing facilities, with each one's last inspection date and whether a Form 483 was issued. Registration is a status a facility elects. It does not turn a compounded drug into an approved one.

The bulks lists

Neither kind of compounder can use any ingredient it likes.

Under 503A, a bulk drug substance must do one of three things: comply with an applicable United States Pharmacopeia or National Formulary monograph, be a component of an FDA-approved drug, or appear on the FDA's 503A bulks list. Substances get onto that list through rulemaking, after consultation with the Pharmacy Compounding Advisory Committee. A final rule in February 2019 placed six substances on it.

While nominations wait, the FDA sorts them into interim categories. Category 1 holds substances under evaluation, where the agency does not intend to act against a compounder that meets its conditions. Category 2 holds substances flagged for significant safety risks. Category 3 holds substances nominated without enough supporting information. This is the machinery behind most of 2026's peptide news: the removal of 12 peptides from Category 2 in April, and an advisory vote on seven of them in July. A favorable vote is not a listing, and we could find no proposed or final rule adding any of them as of this writing.

Under 503B, the test is different. An outsourcing facility may compound from a bulk substance only if the substance appears on a list of substances for which the FDA has found a clinical need, or if the drug is on the agency's shortage list at the time.

One more limit applies to both. Biological products licensed under the Public Health Service Act are not eligible for either exemption, which matters for this field because the FDA treats amino acid chains longer than 40 residues as proteins. Our guide to FDA approval explains that line.

Research use only: a different thing entirely

Research-use material is not a third kind of compounding. No pharmacist prepares it, no prescription triggers it, and neither bulks list governs it. It is sold on the representation that it is for laboratory research and not for human or veterinary use.

Federal regulations do provide for shipping a new drug for in vitro tests or laboratory animal research, under 21 CFR 312.160, with a required caution label, due diligence about the recipient and shipping records. What the label cannot do is override the rest of the evidence. In August 2026 the FDA told five online sellers that their research-use statements did not change its finding that the products were intended for people, based on what their websites said.

The practical difference is where quality comes from. A 503B facility works under manufacturing rules and FDA inspection. A 503A pharmacy works under state pharmacy law. A research supplier works under whatever it chooses to document, which is why a lot-matched certificate of analysis carries so much of the load in that lane. Our pieces on what research use only means and whether research peptides are legal go further.

Why the distinction matters

Nearly every regulatory headline about peptides this year has been about the 503A lane: which substances pharmacies may compound for patients with prescriptions. None of it reaches material sold online as research chemicals.

Frequently asked questions

What is the difference between 503A and 503B?

A 503A pharmacy compounds for an identified patient with a prescription and is overseen mainly by its state board of pharmacy. A 503B outsourcing facility registers with the FDA, follows current good manufacturing practice, is inspected by the agency and may supply health care providers without patient-specific prescriptions.

Is a compounded drug FDA-approved?

No. The FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed. That is true for 503A and 503B alike.

What is the 503A bulks list?

It is the FDA's list of bulk substances that pharmacies may compound with even though the substance has no pharmacopeial monograph and is not part of an approved drug. Substances are added by rulemaking.

Where do research-use-only peptides fit?

Outside both sections. They are not compounded drugs, they are not dispensed by a pharmacy, and they are not approved for human use.

Sources:

Nothing here is legal or medical advice. Research use only.

For research use only · Not for human or veterinary use · No research compound discussed here is FDA-approved for any indication